Associations of TNFR1 with kidney function outcomes by age, gender, and baseline kidney function status: Data from the Heart and Soul Study. by Park, Meyeon et al.
UCSF
UC San Francisco Previously Published Works
Title
Associations of TNFR1 with kidney function outcomes by age, gender, 
and baseline kidney function status: Data from the Heart and Soul 
Study.
Permalink
https://escholarship.org/uc/item/3tj0z02q
Authors
Park, Meyeon
Maristany, Daniela
Huang, Debbie
et al.
Publication Date
2017-10-01
DOI
10.1016/j.dib.2017.07.048
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Contents lists available at ScienceDirect
Data in Brief
Data in Brief 14 (2017) 366–370http://d
2352-34
(http://c
DOI
n Corr
E-mjournal homepage: www.elsevier.com/locate/dibData ArticleAssociations of TNFR1 with kidney function
outcomes by age, gender, and baseline
kidney function status: Data from
the Heart and Soul Study
Meyeon Park n,a,b, Daniela Maristany c, Debbie Huang a,
Michael G. Shlipak b,d,e, Mary Whooley b,d,e
a Division of Nephrology, University of California, San Francisco, San Francisco, CA, USA
b Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA,
USA
c School of Medicine, University of California, San Francisco, San Francisco, CA, USA
d San Francisco VA Medical Center, San Francisco, CA, USA
e Department of Medicine, University of California, San Francisco, San Francisco, CA, USAa r t i c l e i n f o
Article history:
Received 18 May 2017
Received in revised form
15 July 2017
Accepted 20 July 2017
Available online 26 July 2017
Keywords:
Kidney disease
Biomarkers
Datax.doi.org/10.1016/j.dib.2017.07.048
09/& 2017 The Authors. Published by Elsev
reativecommons.org/licenses/by/4.0/).
of original article: http://dx.doi.org/10.1016
esponding author.
ail address: meyeon.park@ucsf.edu (M. Parka b s t r a c t
Tumor necrosis factor receptor type 1 (TNFR1) is associated with
kidney disease and mortality risk in various populations [1,2]. We
evaluated associations of TNFR1 with mortality and mediators of
this relationship in doi: 10.1016/j.atherosclerosis.2017.05.021.
Whether or not these associations are influenced by age, gender, or
baseline kidney function are not known. We evaluated associations
of TNFR1 levels with measures of kidney function stratifying by
these variables. Our outcomes included estimated glomerular fil-
tration rate (eGFR) o 60 ml/min/1.73 m2, albumin to creatinine
ratio (ACR) 430 mg/g, and rapid kidney function loss, defined as a
change in eGFR of greater than 3% per year.
& 2017 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).ier Inc. This is an open access article under the CC BY license
/j.atherosclerosis.2017.05.021
).
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 Tumor necrosis factor receptors 1 (TNFR1) [1,2] and 2 (TNFR2) are cell membrane-bound receptors
involved in apoptosis, inflammation, and immune host defense [3].
 The soluble TNF receptors are present in the sera of healthy individuals, and elevated levels occur
in a variety of pathologic states including sepsis and autoimmune disorders [4].
 Associations between TNFR1 and kidney function outcomes are uniformly strong [2,5,6].1. Data
Our data include three tables describing incident rate ratios for associations of quartiles of TNFR1
with three outcomes: eGFR o 60 ml/min/1.73 m2 (Table 1), ACR 430 mg/g (Table 2), and rapid
kidney function loss by subgroups (age, gender, and baseline kidney function assessed by eGFR and
ACR) (Table 3). Multivariable models were conducted adjusting for demographics (Model 1);
comorbid conditions (Model 2), and either baseline ACR for the outcomes of eGFR o 60 and rapid
kidney function loss or baseline eGFR for the outcome of ACR 4 30 mg/g (Model 3). Table 4 provides
the p-values for interaction for these associations by age, gender, and eGFR or ACR at baseline.2. Experimental design, materials and methods
The Heart and Soul Study was a prospective cohort study designed to investigate the effects of
psychosocial factors on health outcomes in patients with stable ischemic heart disease (IHD) [7].
Participants were eligible if they had a history of myocardial infarction; angiographic evidence of
Z50% stenosis in Z1 coronary vessels; evidence of exercise-induced ischemia by treadmill ECG or
stress nuclear perfusion imaging; or a history of coronary revascularization. Participants were
excluded if they were unable to walk one block, had an acute coronary syndrome within the previous
six months, or were likely to move out of the area within three years. 1024 subjects were recruited
from 12 outpatient clinics in the San Francisco Bay Area between 9/2000 and 12/2002. Participants
were divided into quartiles of TNFR1 levels. TNFR1 levels were normally distributed in the population
Table 1
Associations between baseline quartiles of TNFR1 and CKD assessed by eGFR o 60 ml/min/1.73 m2, by subgroups.
Q1 Q2 Q3 Q4
OR (95% CI) OR (95% CI) OR (95% CI)
Men
Model 1 (n¼798) Ref 2.31 (1.07, 5.01) 5.89 (2.89, 12.02) 13.41 (6.65, 27.07)
Model 2 (n¼730) Ref 2.00 (0.93, 4.30) 4.65 (2.27, 9.54) 9.67 (4.73, 19.78)
Model 3a (n¼695) Ref 2.86 (1.13, 7.22) 6.61 (2.71, 16.14) 13.04 (5.31, 32.02)
Women
Model 1 (n¼182) Ref 2.80 (0.76, 10.33) 4.94 (1.41, 17.33) 12.90 (4.11, 40.48)
Model 2 (n¼151) Ref 1.72 (0.43, 6.84) 4.25 (1.14, 15.88) 8.99 (2.54, 31.79)
Model 3a (n¼138) Ref 2.23 (0.45, 11.08) 5.22 (1.11, 24.61) 9.06 (1.98, 41.37)
Age 4 67 years
Model 1 (n¼482) Ref 1.58 (0.77, 3.26) 3.19 (1.66, 6.15) 6.61 (3.55, 12.33)
Model 2 (n¼433) Ref 1.38 (0.68, 2.76) 2.70 (1.44, 5.07) 5.01 (2.72, 9.23)
Model 3a (n¼408) Ref 1.84 (0.82, 4.12) 3.47 (1.63, 7.40) 6.02 (2.84, 12.80)
Age o ¼67 years
Model 1 (n¼482) Ref 5.08 (1.10, 23.50) 16.18 (3.86, 67.80) 57.14 (14.29, 228.55)
Model 2 (n¼433) Ref 3.55 (0.73, 17.33) 12.87 (2.93, 56.60) 39.33 (9.46, 163.45)
Model 3a (n¼408) Ref 5.64 (0.66, 48.02) 23.26 (177.26) 64.88 (8.97, 469.28)
ACR Z 30 mg/g
Model 1 (n¼150) Ref 3.49 (0.53, 23.04) 5.95 (0.95, 37.17) 9.89 (1.60, 61.10)
Model 2 (n¼125) Ref 2.05 (0.34, 12.53) 4.38 (0.77, 25.03) 7.23 (1.30, 40.16)
ACR o 30 mg/g
Model 1 (n¼768) Ref 2.89 (1.19, 7.01) 7.35 (3.20, 16.91) 16.50 (7.23, 37.65)
Model 2 (n¼708) Ref 2.61 (1.10, 6.21) 6.30 (2.78, 14.27) 12.12 (5.27, 27.88)
Model 1: Adjusted for demographic factors (age, sex, race)
Model 2: Model 1 þ comorbid conditions (smoking, BMI, history of hypertension, diabetes, MI, HF, ACEI/ARB use, beta-blocker
use, HDL, triglycerides, hemoglobin A1c, LVEF, METs)
Model 3a: Model 2 þ ACR
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itudinal rapid kidney function loss using Poisson regression. We compared rates of the outcomes of
MI, HF, and mortality between quartile 4 versus quartile 1 using multivariable Poisson regression
models. For all regression models, adjustment variables included demographic characteristics (age,
sex, race); lifestyle characteristics (smoking, BMI); and comorbid conditions (history of hypertension,
diabetes, MI, HF, ACEI/ARB use, beta-blocker use, HDL, triglycerides, hemoglobin A1c, LVEF, METs).
Covariates were selected based on evaluation of known confounders of atherosclerosis and kidney
disease. In analyses of rapid kidney function loss, we adjusted for the baseline value and additionally
adjusted for ACR in the final model. We then performed subgroup analyses by gender, age, and
baseline kidney function.
Table 2
Associations between baseline quartiles of TNFR1 and ACR 4¼30, by subgroups.
Q1 Q2 Q3 Q4
OR (95% CI) OR (95% CI) OR (95% CI)
Men
Model 1 (n¼757) Ref 2.00 (1.00, 4.00) 2.76 (1.39, 5.48) 6.25 (3.31, 11.79)
Model 2 (n¼698) Ref 1.94 (0.89, 4.21) 2.00 (0.91, 4.41) 3.16 (1.43, 7.01)
Model 3b (n¼695) Ref 1.88 (0.82, 4.31) 1.69 (0.72, 3.97) 2.00 (0.81, 4.94)
Women
Model 1 (n¼165) Ref 2.37 (0.76, 7.42) 2.37 (0.67, 8.42) 5.71 (2.10, 15.57)
Model 2 (n¼139) Ref 1.47 (0.43, 5.07) 2.18 (0.54, 8.83) 3.30 (0.93, 11.69)
Model 3b (n¼138) Ref 1.53 (0.45, 5.22) 2.53 (0.58, 10.99) 4.74 (1.35, 16.70)
Age 4 67 years
Model 1 (n¼456) Ref 2.02 (0.76, 5.36) 1.97 (0.73, 5.34) 4.78 (1.96, 11.66)
Model 2 (n¼411) Ref 1.84 (0.64, 5.33) 1.53 (0.51, 4.60) 2.68 (0.92, 7.85)
Model 3b (n¼408) Ref 2.00 (0.59, 6.80) 1.45 (0.40, 5.24) 2.08 (0.57, 7.61)
Age o ¼67 years
Model 1 (n¼466) Ref 1.95 (0.91, 4.15) 3.25 (1.57, 6.72) 7.21 (3.77, 13.80)
Model 2 (n¼426) Ref 1.45 (0.64, 3.27) 2.80 (1.27, 6.16) 3.81 (1.68, 8.65)
Model 3b (n¼425) Ref 1.44 (0.63, 3.30) 2.72 (1.21, 6.09) 3.57 (1.36, 9.39)
eGFRo60
Model 1 (n¼277) Ref 2.04 (0.27, 15.67) 1.55 (0.21, 11.53) 2.69 (0.38, 19.21)
Model 2 (n¼244) Ref 1.09 (0.13, 9.34) 1.03 (0.12, 8.81) 1.41 (0.18, 11.24)
eGFR 4¼60
Model 1 (n¼641) Ref 2.00 (1.04, 3.86) 2.66 (1.30, 5.43) 4.75 (2.30, 9.82)
Model 2 (n¼589) Ref 1.60 (0.79, 3.25) 1.62 (0.75, 3.51) 1.91 (0.78, 4.69)
Model 1: Adjusted for demographic factors (age, sex, race)
Model 2: Model 1 þ comorbid conditions (smoking, BMI, history of hypertension, diabetes, MI, HF, ACEI/ARB use, beta-blocker
use, HDL, triglycerides, hemoglobin A1c, LVEF, METs)
Model 3b: Model 2 þ eGFR
Table 3
Associations between baseline quartiles of TNFR1 and Rapid Loss in Kidney Function, by subgroups.
Q1 Q2 Q3 Q4
OR (95% CI) OR (95% CI) OR (95% CI)
Men
Model 1 (n¼514) Ref 1.26 (0.68, 2.35) 1.60 (0.84, 3.04) 3.79 (2.00, 7.16)
Model 2 (n¼477) Ref 1.20 (0.64, 2.27) 1.41 (0.74, 2.69) 2.70 (1.39, 5.23)
Model 3b (n¼457) Ref 1.10 (0.57, 2.11) 2.11 (0.64, 2.30) 2.25 (1.13, 4.46)
Women
Model 1 (n¼113) Ref 1.28 (0.39, 4.26) 0.96 (0.19, 4.71) 2.16 (0.64, 7.31)
Model 2 (n¼100) Ref 1.18 (0.34, 4.13) 0.20 (0.03, 1.20) 0.79 (0.19, 3.26)
Model 3b (n¼93) Ref 1.45 (0.49, 4.28) 0.16 (0.02, 1.31) 0.47 (0.08, 2.81)
Age 4 67 years
Model 1 (n¼291) Ref 1.75 (0.70, 4.33) 1.73 (0.66, 4.55) 3.46 (1.33, 8.98)
Model 2 (n¼271) Ref 1.84 (0.74, 4.56) 1.78 (0.68, 4.64) 2.94 (1.10, 7.83)
Model 3b (n¼257) Ref 1.88 (0.69, 5.11) 1.74 (0.63, 4.81) 2.77 (0.97, 7.92)
Age o ¼67 years
Model 1 (n¼336) Ref 0.95 (0.45, 2.04) 1.30 (0.59, 2.85) 3.97 (1.98, 7.95)
Model 2 (n¼306) Ref 0.84 (0.39, 1.78) 1.00 (0.46, 2.18) 2.51 (1.18, 5.33)
Model 3b (n¼293) Ref 0.85 (0.39, 1.84) 0.94 (0.42, 2.12) 2.23 (1.03, 5.23)
Model 1: Adjusted for demographic factors (age, sex, race)
Model 2: Model 1 þ comorbid conditions (smoking, BMI, history of hypertension, diabetes, MI, HF, ACEI/ARB use, beta-blocker
use, HDL, triglycerides, hemoglobin A1c, LVEF, METs)
Model 3b: Model 2 þ eGFR
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Table 4
P-values for interaction.
interaction term outcome
eGFRo60
outcome
ACR430
outcome rapid
loss
TNFR1*age 0.0004 0.59 0.3
TNFR1*gender 0.95 0.79 0.77
TNFR1*eGFRbaseline n/a 0.96 n/a
TNFR1*ACRbaseline 0.71 n/a 0.53
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